<DOC>
	<DOC>NCT00520806</DOC>
	<brief_summary>Different doses of relaxin will be compared to placebo to determine efficacy and safety for the treatment of patients hospitalized with acute heart failure</brief_summary>
	<brief_title>Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure</brief_title>
	<detailed_description>This is an international, randomized, double-blind, placebo-controlled, Phase II/III trial of intravenous recombinant relaxin for the treatment of signs and symptoms in patients hospitalized for acute decompensated heart failure. The Phase II pilot study has completed; the Phase III main portion of the trial is ongoing.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Methocarbamol</mesh_term>
	<criteria>Hospitalized for acute heart failure Dyspnea at rest or with minimal exertion Pulmonary congestion Able to provide informed consent Systolic blood pressure &gt; 125 mmHg Impaired renal function defined as an eGFR of 3075 mL/min/1.73m2 Use of other IV therapies for acute heart failure Fever or sepsis Recent major neurologic event Recent major surgery Recent acute coronary syndrome Other recent investigational drug use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Renal dysfunction</keyword>
	<keyword>Relaxin</keyword>
	<keyword>Vasodilator</keyword>
</DOC>